New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions

Summary

Four recently introduced new oral anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban) have been shown to be at least as efficacious and safe as warfarin for stroke prevention in patients with atrial fibrillation in their respective trials. The first three have been approved, while edoxaban is awaiting regulatory approval. Several guidelines have endorsed the approved new oral anticoagulants over warfarin because of their favourable risk-benefit ratio, low propensity for food and drug interactions, and lack of requirement for routine coagulation monitoring. In this invited review, we summarise the results of the four studies and discuss widely held conclusions. We take a step further and discuss how differences in study design, analysis plan, and unexpected events affect the interpretation of the study results. Finally, we take our re-interpretation of study results and discuss how they might impact clinical practice and anticoagulant choice for patients.

Keywords

Clinical trials - oral anticoagulants - stroke / prevention - thrombosis

• References

• 1 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2009; 361: 1139-1151.
• 2 Patel MR, Mahaffey KW, Garg J. et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med 2011; 365: 883-891.
• 3 Granger CB, Alexander JH, McMurray JJV. et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2011; 365: 981-992.
• 4 Giugliano RP, Ruff CT, Braunwald E. et al. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2013; 369: 2093-2104.
• 5 Connolly SJ, Eikelboom J, Joyner C. et al. Apixaban in Patients with Atrial Fibrillation. N Engl J Med 2011; 364: 806-817.
• 6 Camm AJ, Lip GYH, De Caterina R. et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillationDeveloped with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-2747.
• 7 You JJ, Singer DE, Howard PA. et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic therapy and prevention of thrombosis, 9th ed: american college of chest physicians evidence-based clinical practice guidelines. Chest 2012; 141 (02) Suppl e531S-e75S.
• 8 Skanes AC, Healey JS, Cairns JA. et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Canad J Cardiol 2012; 28: 125-136.
• 9 Furie KL, Goldstein LB, Albers GW. et al. Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation: A Science Advisory for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2012; 43: 3442-3453.
• 10 Dentali F, Riva N, Crowther M. et al. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation 2012; 126: 2381-2391.
• 11 Lip GY, Larsen TB, Skjoth F. et al. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol 2012; 60: 738-746.
• 12 Mantha S, Ansell J. An indirect comparison of dabigatran, rivaroxaban and api-xaban for atrial fibrillation. Thromb Haemost 2012; 108: 476-484.
• 13 Rasmussen LH, Larsen TB, Graungaard T. et al. Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis. Br Med J 2012; 345: e7097.
• 14 Dogliotti A, Paolasso E, Giugliano RP. Novel oral anticoagulants in atrial fibrillation: a meta-analysis of large, randomized, controlled trials vs warfarin. Clin Cardiol 2013; 36: 61-67.
• 15 Capodanno D, Capranzano P, Giacchi G. et al. Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: a meta-analysis of 50,578 patients. Int J Cardiol 2013; 167: 1237-1241.
• 16 Ruff CT, Giugliano RP, Braunwald E. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2013 Epub ahead of print doi:10.1016/s0140–6736(13)62343–0.
• 17 Southworth MR, Reichman ME, Unger EF. Dabigatran and Postmarketing Reports of Bleeding. N Engl J Med 2013; 368: 1272-1274.
• 18 Larsen TB, Rasmussen LH, Skjøth F. et al. Efficacy and Safety of Dabigatran Et-exilate and Warfarin in “Real-World” Patients With Atrial FibrillationA Prospective Nationwide Cohort Study. J Am Coll Cardiol 2013; 61: 2264-2273.
• 19 Sørensen R, Gislason G, Torp-Pedersen C. et al. Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. Br Med J Open 2013; 3.
• 20 Banerjee A, Lane DA, Torp-Pedersen C. et al. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost 2012; 107: 584-589.
• 21 Pisters R, Nieuwlaat R, Lane DA. et al. Potential net clinical benefit of population-wide implementation of apixaban, dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey. Thromb Haemost 2013; 109: 328-336.
• 22 Food and Drug Administration. Rivaroxaban Clinical Review. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202439Orig1s000MedR.pdf Accessed 8/10/2013.
• 23 Food and Drug Administration. Dabigatran Medical Review. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022512orig1s000medr.pdf Accessed 22/10/13.
• 24 Food and Drug Administration. Apixaban Clinical Review. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202155Orig1s000MedR.pdf Accessed 8/10/2013.
• 25 Chatterjee S, Sardar P, Biondi-Zoccai G. et al. New Oral Anticoagulants and the Risk of Intracranial Hemorrhage: Traditional and Bayesian Meta-analysis and Mixed Treatment Comparison of Randomized Trials of New Oral Anticoagulants in Atrial Fibrillation. JAMA Neurol 2013; 70: 1486-1490.
• 26 Desai J, Kolb JM, Weitz JI. et al. Gastrointestinal bleeding with the new oral anti-coagulants--defining the issues and the management strategies. Thromb Hae-most 2013; 110: 205-212.
• 27 Holster IL, Valkhoff VE, Kuipers EJ. et al. New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. Gastroenterology 2013; 145: 105-112. e15.
• 28 Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: Meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012; 172: 397-402.
• 29 Hohnloser SH, Oldgren J, Yang S. et al. Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial. Circulation 2012; 125: 669-676.
• 30 Hart RG, Diener H-C, Yang S. et al. Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or Dabigatran: The RELY Trial. Stroke 2012; 43: 1511-1517.
• 31 Hankey GJ, Stevens S, Piccini JP. et al. Predictors of Intracranial Hemorrhage Among Anticoagulated Patients with Atrial Fibrillation: Insights from the Riva-roxaban Once-daily oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Available at: http://stroke.ahajournals.org/cgi/content/meet-ing_abstract/43/2_MeetingAbstracts/A152 Accessed 08/10/2013.
• 32 Dale B, Eikelboom JW, Weitz JI. et al. Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?. J Thromb Thrombolysis 2013; 35: 295-301.
• 33 Blech S, Ebner T, Ludwig-Schwellinger E. et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metabol Dispos 2008; 36: 386-399.
• 34 Weinz C, Schwarz T, Kubitza D. et al. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metabol Dis-pos 2009; 37: 1056-1064.
• 35 Zhang D, He K, Raghavan N. et al. Comparative metabolism of 14C–labeled apixaban in mice, rats, rabbits, dogs, and humans. Drug Metabol Dispos 2009; 37: 1738-1748.
• 36 Bathala MS, Masumoto H, Oguma T. et al. Pharmacokinetics, biotrans-formation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metabol Dispos 2012; 40: 2250-2255.
• 37 Eikelboom JW, Wallentin L, Connolly SJ. et al. Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial. Circulation 2011; 123: 2363-2372.
• 38 Hylek EM, Held C, Alexander JH. et al. Reduction in Bleeding with Apixaban versus Warfarin is Consistent Across Subgroups and Locations: Insights from the ARISTOTLE Trial. Available at: http://circ.ahajournals.org/cgi/content/meeting_abstract/126/21_MeetingAbstracts/A15115 Accessed 15 Jan 2014.
• 39 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation. Ann Intern Med 2007; 146: 857-867.